,bevacizumab,trastuzumab deruxtecan
astrazeneca,daiichi sankyo,roche
['#gi', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'breast', 'destinybreast04', 'gi ']
 live footage of #gi oncologists applauding at the #asco22 plenary for the 6 months os gain in #destinybreast04 after yet another trial comparing first line doublet + egfri or bev in #mcrc with minimal differences between arms 
MD - GI oncology @uzleuven @KU_Leuven